诺思格8月28日获融资买入1942.17万元，融资余额8669.17万元

Core Viewpoint - The company Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. has shown stable financial performance with slight growth in revenue and net profit, while also experiencing significant trading activity in its stock. Group 1: Financial Performance - For the period from January to June 2025, Norse Group achieved operating revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the company's A-share listing amounted to 49.50 million yuan [3] Group 2: Business Operations - The company's main business segments include clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] - As of June 30, 2025, the number of shareholders increased to 10,400, up by 2.06% from the previous period, while the average circulating shares per person decreased by 1.97% to 5,486 shares [2] Group 3: Stock Trading Activity - On August 28, Norse Group's stock price fell by 0.39%, with a trading volume of 149 million yuan [1] - The financing buy-in amount for Norse Group on the same day was 19.42 million yuan, with a net buy of 5.95 million yuan after 13.47 million yuan in financing repayments [1] - The total financing and securities lending balance reached 86.69 million yuan, accounting for 2.94% of the circulating market value, indicating a high level compared to the past year [1]